Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Solid Tumors

About this trial
This is an interventional treatment trial for Solid Tumors
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC)
- Performance status as follows: Participantss aged >= 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participantss aged 16 to < 18 years: Karnofsky score >= 50%; Participants aged < 16 years: Lansky score >= 50%
- For participants aged >= 18 and <18 years: adequate hematologic and end-organ function
- Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- Adequate recovery from most recent systemic or local treatment for cancer
- Life expectancy >= 8 weeks
- Ability to comply with the study protocol, in the investigator's judgment
- For female participants of childbearing potential: Negative serum pregnancy test <= 14 days prior to initiating study treatment; agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
- For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
- In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort
Exclusion Criteria:
- Current participation or enrollment in another therapeutic clinical trial
- Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
- Whole brain radiotherapy within 14 days prior to start of study treatment
- Stereotactic radiosurgery within 7 days prior to start of study treatment
- Pregnant or breastfeeding, or intending to become pregnant during the study
- History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
- Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
- In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
Sites / Locations
- Southern Cancer CenterRecruiting
- Western Regional Medical Center at Cancer Treatment Centers of AmericaRecruiting
- City of Hope National Medical Center
- Kaiser Permanente Los Angeles; Clinic/Infusion -LA
- USC Norris Cancer CenterRecruiting
- Hoag Memorial HospitalRecruiting
- UC Davis Comprehensive Cancer CenterRecruiting
- University of California at San Francisco
- Sarcoma Oncology CenterRecruiting
- Children's Hospital Colorado; Center For Cancer/Blood DisorderRecruiting
- Christiana Care Health Srvcs; Helen F Graham Can Center
- University of Florida
- Miami Cancer Institute of Baptist Health, Inc.Recruiting
- Ocala Oncology CenterRecruiting
- University Cancer & Blood Center, LLC; ResearchRecruiting
- St. AlphonsusRecruiting
- Midwestern Regional Med Center
- Horizon Oncology Research, Inc.
- New England Cancer Specialists
- Maryland Hematology & Oncology. P.A.Recruiting
- St. Joseph Mercy HospitalRecruiting
- Henry Ford Health SystemRecruiting
- University of Minnesota
- Metro-Minnesota Community Oncology Research ConsortiumRecruiting
- Washington University
- St. Vincent Frontier Cancer CenterRecruiting
- Comprehensive Cancer Centers of Nevada - Eastern Avenue
- Dartmouth Hitchcock Medical CenterRecruiting
- Rutgers Cancer Institute of New JerseyRecruiting
- University of New Mexico; Comprehensive Cancer CenterRecruiting
- Montefiore Einstein Center for Cancer CareRecruiting
- Eastchester Center for Cancer Care
- New York Cancer and Blood Specialists - Setauket Medical Oncology
- National Translational Research Group
- Icahn School of Medicine at Mount SinaiRecruiting
- Memorial Sloan Kettering Cancer Center
- Levine Cancer Institute
- Barrett Cancer Center
- Oncology Hematology Care IncRecruiting
- Providence Portland Medical Center
- Consultants in Medical Oncology and HematologyRecruiting
- Alliance Cancer SpecialistsRecruiting
- The Children's Hospital of PhiladelphiaRecruiting
- Cancer Treatment Centers of America; Eastern Regional Medical Center
- PRISMA Health - Greenville
- The West Clinic; West Cancer CenterRecruiting
- St. Jude Children'S Research HospitalRecruiting
- Texas Onc-Central Austin CA CtRecruiting
- Mary Crowley Medical Research CenterRecruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterRecruiting
- Cook Childrens Medical CenterRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
- Texas Oncology- Northeast TexasRecruiting
- Virginia Cancer Specialists - LeesburgRecruiting
- Northwest Medical Specialties, PLLC; Research DepartmentRecruiting
- Froedtert and The Medical College of WisconsinRecruiting
- Kinghorn Cancer Centre; St Vincents HospitalRecruiting
- Sydney Children's HospitalRecruiting
- Royal Darwin Hospital; Alan Walker Cancer CentreRecruiting
- Princess Alexandra HospitalRecruiting
- Peter MacCallum Cancer Centre; Medical Oncology
- Royal Children's HospitalRecruiting
- Cliniques Universitaires St-LucRecruiting
- GHdC Site Notre DameRecruiting
- UZ Antwerpen
- UZ GentRecruiting
- UZ Leuven Gasthuisberg
- Hospital Moinhos de VentoRecruiting
- Hospital Sírio-Libanês
- Hospital Sírio-LibanêsRecruiting
- Hospital A. C. Camargo; OncologiaRecruiting
- Clínica Onco Star - Rede D'OrRecruiting
- BC Cancer ? Vancouver
- London Health Sciences Centre · Victoria Hospital; Department of MedicineRecruiting
- The Ottawa Hospital - General CampusRecruiting
- The Hospital for Sick ChildrenRecruiting
- Princess Margaret Cancer CenterRecruiting
- McGill University Health CenterRecruiting
- Beijing Children's Hospital, Capital Medical University; Oncological Surgery DepartmentRecruiting
- Beijing Cancer HospitalRecruiting
- The First Hospital of Jilin UniversityRecruiting
- Jilin Cancer HospitalRecruiting
- West China Hospital - Sichuan UniversityRecruiting
- Zhongshan Hospital Fudan UnvierstiyRecruiting
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineRecruiting
- Shanghai East Hospital
- Tianjin Cancer HospitalRecruiting
- First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityRecruiting
- Aarhus Universitetshospital; KræftafdelingenRecruiting
- Rigshospitalet; Onkologisk KlinikRecruiting
- Institut Bergonie; OncologieRecruiting
- Centre Oscar Lambret; Service de Pediatrie
- CENTRE LEON BERARD; Département d?Hématologie et d?Oncologie
- Hopital de la TimoneRecruiting
- Institut Universitaire du Cancer de Toulouse-Oncopole
- Institut de Cancerologie Gustave-Roussy (IGR)
- Uniklinik EssenRecruiting
- Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I
- Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & OnkologieRecruiting
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik IIRecruiting
- Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und HepatologieRecruiting
- SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.Recruiting
- Praxis für Hämatologie, Onkologie und PalliativmedizinRecruiting
- Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik IIIRecruiting
- Universtitätsklinikum Ulm; Klinik für Innere Medizin IIIRecruiting
- Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTURecruiting
- Hong Kong Children's HospitalRecruiting
- Prince of Wales Hospital; Department of Clinical OnocologyRecruiting
- Rambam Health Care Campus; OncologyRecruiting
- Hadassah University Hospital - Ein Kerem
- Rabin MC; Davidof Center - Oncology InstituteRecruiting
- Sheba Medical CenterRecruiting
- Sourasky / Ichilov Hospital; Dept. of OncologyRecruiting
- Istituto Nazionale Tumori Fondazione G. PascaleRecruiting
- Ospedale Pediatrico Bambino Gesù - IRCCS; Dipartimento di Onco-Ematologia PediatricaRecruiting
- Policlinico Universitario Agostino Gemelli IRCCS; UOS Fase 1
- Asst Degli Spedali Civili Di Brescia
- Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1Recruiting
- Istituto Nazionale Tumori di Milano; S.C. Oncologia PediatricaRecruiting
- Dipartimento di Scienze Pediatriche Adolescenza; Osp. Infantile Regina MargheritaRecruiting
- Azienda Ospedaliera Meyer; Centro di Eccellenza di Oncologia ed Ematologia PediatricaRecruiting
- Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia OncologicaRecruiting
- National Cancer Center Hospital East
- Kindai University Hospital
- National Cancer Center Hospital
- Seoul National University Bundang Hospital
- Seoul National University Hospital- Adult SiteRecruiting
- Seoul National University Hospital- Pediatric SiteRecruiting
- Severance Hospital, Yonsei University Health SystemRecruiting
- Asan Medical Center
- Samsung Medical Center- Adult Site
- Samsung Medical Center- Pediatric SiteRecruiting
- Prinses Maxima Centrum
- Auckland City Hospital, Cancer and Blood ResearchRecruiting
- Christchurch Hospital; Dept of Oncology
- Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
- Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki PiersRecruiting
- IPO do Porto; Servico de Oncologia Medica
- PanOncology Trials; Hospital Oncológico, Puerto Rico Medical CenterRecruiting
- National University Hospital; National University Cancer Institute, Singapore (NCIS)Recruiting
- National Cancer Centre; Medical Oncology
- Hospital Sant Joan De DeuRecruiting
- Hospital Univ Vall d'Hebron; Servicio de OncologiaRecruiting
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona
- Hospital Infantil Universitario Nino JesusRecruiting
- Clinica Universidad de Navarra Madrid; Servicio de OncologíaRecruiting
- START Madrid-FJD, Hospital Fundacion Jimenez Diaz
- Hospital Universitario 12 de Octubre; Servicio de Oncologia
- Hospital Universitario La Paz; Servicio de OncologiaRecruiting
- START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
- Hospital Universitario la Fe; Servicio de OncologiaRecruiting
- Universitätsspital Basel (USB)
- Ospedale Regionale di Bellinzona Medizin Onkologie
- Inselspital, Klinik und Poliklinik für Medizinische Onkologie
- Unversitätsspital Zürich
- National Cheng Kung University Hospital; OncologyRecruiting
- Taipei Veterans General Hospital; Department of OncologyRecruiting
- Chang Gung Memorial Hospital-Linkou; Dept of OncologyRecruiting
- National Taiwan University Hospital; Oncology
- Beatson West of Scotland Cancer CentreRecruiting
- University College London HospitalRecruiting
- Royal Manchester Children?s HospitalRecruiting
- The Christie NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)
Cohort B: NTRK1/2/3 fusion-positive tumors
Cohort C: ALK fusion-positive tumors (excluding NSCLC)
Cohort D: TMB-high tumors
Cohort E: AKT1/2/3 mutant-positive tumors
Cohort F: HER2 mutant-positive tumors
Cohort G: MDM2-amplified, TP53 wild-type tumors
Cohort H: PIK3CA multiple mutant-positive tumors
Cohort I: BRAF class II mutant or fusion-positive tumors
Cohort J: BRAF class III mutant-positive tumors
Cohort K: RET fusion-positive tumors (excluding NSCLC)
Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)
Cohort M: ATM Loss of Function tumors
Cohort N: SETD2 Loss of Function tumors
Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment
Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed for enrollment
Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days. Note: Cohort F has been closed for enrollment
Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle. Note: Cohort G has been closed for enrollment
Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.
Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment
Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Participants with KRAS G12C-positive tumors will self-administer GDC-6036 orally at home (except on clinic days).
Participants with ATM Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
Participants with SETD2 Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).